Ikuo Hirano
Gastroenterology · Chicago, ILNPI 1538195185
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Sanofi at 26.7% of the total. Reporting peaked in 2022 at $170,051 and has fallen 53.1% since, to $79,832 in 2024. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $1834.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$122K
- Regeneron Healthcare Solutions, Inc.$120K
- Astrazeneca UK Limited$70K
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- Bristol Myers Squibb$29K
- Sanofi-aventis U.S. LLC$17K
- plus $52K from 12 others
Across 217 payments — averaging $6615.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$542K
- Bristol Myers Squibb$364K
- Takeda Pharmaceuticals U.S.A., Inc.$214K
- Shire North American Group Inc$128K
- AstraZeneca$125K
- Pfizer$46K
- plus $17K from 1 others
What the payments were for
- Consulting fees$258,08356%
- Speaking & faculty fees$157,76335%
- Travel & lodging$36,8868%
- Food & beverage$4,1051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 41 | $122,016 |
| Regeneron Healthcare Solutions, Inc. | 98 | $120,049 |
| Astrazeneca UK Limited | 7 | $70,126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $46,363 |
| Bristol Myers Squibb | 8 | $29,065 |
| Sanofi-aventis U.S. LLC | 3 | $16,824 |
| E.r. Squibb & Sons, L.L.C. | 7 | $13,423 |
| Phathom Pharmaceuticals, Inc. | 10 | $8,128 |
| Regeneron | 4 | $6,084 |
| Adare Pharmaceuticals, Inc. | 17 | $5,813 |
| Shire North American Group Inc | 4 | $5,557 |
| Boston Scientific | 5 | $4,533 |
| AstraZeneca | 12 | $3,986 |
| AbbVie | 3 | $1,850 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $1,200 |
| Astrazeneca AB | 1 | $669 |
| GSK | 1 | $650 |
| Pfizer | 1 | $500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$456,837 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 77 | $1,356 |
| Pantoprazole Sodium | 15 | $374 |
| Famotidine | 14 | $81 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Chicago
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
- Christopher ChapmanChicago$645K
- Saurabh KapurChicago$532K
- Adam SteinChicago$438K
- John PandolfinoChicago$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.